kla-RITH-roe-mye-sin
Therapeutic Classification: agents for atypical mycobacterium, anti-infectives, antiulcer agents
Pharmacologic Classification: macrolides
REMS
Mycobacterium avium
complex (MAC) (in combination with ethambutol).Spectrum:
Absorption: Rapidly absorbed (50%) after oral administration.
Distribution: Widely distributed; tissue levels may exceed those in serum.
Protein Binding: 65–70%.
Half-Life: Dose-dependent and prolonged with renal dysfunction 250-mg dose: 3–4 hr; 500-mg dose: 5–7 hr.
Contraindicated in:
Use Cautiously in:
CV: QT interval prolongation, TORSADES DE POINTES
Derm: ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS, DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), pruritus, rash, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS
GI: CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD), abdominal pain/discomfort, abnormal taste, diarrhea, dyspepsia, HEPATOTOXICITY, nausea
Neuro: headache
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)
Drug-drug:
H. pylori
: 500 mg 2–3 times daily with a proton pump inhibitor (lansoprazole or omeprazole) with or without amoxicillin for 10–14 days; Endocarditis prophylaxis: 500 mg 1 hr before procedure; MAC prophylaxis/treatment: 500 mg twice daily, for active infection another antimycobacterial is required.Renal Impairment
Lab Test Considerations:
NDC Code